FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324792835> ?p ?o ?g. }

• W2324792835 endingPage "e653" @default.
• W2324792835 startingPage "e653" @default.
• W2324792835 abstract "Patients with “difficult-to-treat” advanced testicular cancer can require multiple therapies. We retrospectively assessed our patients with advanced germ cell tumors (GCTs) and characterized the clinical efficacy, outcomes, and factors affecting overall survival (OS). Two hundred fifty-three patients with advanced GCTs were treated at Kyoto Prefectural University of Medicine, Kyoto, Japan, from June 1998 to September 2013. Of 253 patients, 142 patients had salvage chemotherapy. As first-line therapy, bleomycin, etoposide, and cisplatin, and etoposide and cisplatin therapies were performed in 234 cases (92.5%). As second-line therapy, etoposide, ifosfamide, and cisplatin/vinblastine, ifosfamide, and cisplatin, and paclitaxel, ifosfamide, and cisplatin/paclitaxel, ifosfamide, and nedaplatin therapies were carried out in 44 and 59 cases, respectively. Furthermore, 111, 72, 44, and 28 cases had third, fourth, fifth, and sixth-or-later-line chemotherapy, respectively. Five-year OS rate stratified by chemotherapy line was 95.5% in the first line, 89.4% in the second line, 82.1% in the third line, 45.1% in the fourth line, and 58.9% in the fifth or after line. A statistical significant difference was found when comparing fourth-or-after-line versus first to third-line therapy. Additional procedures were performed, including retroperitoneal lymph node dissection (RPLND) (n = 168), extra-RPLN resection (n = 114), and external beam radiotherapy/stereotactic radiotherapy (n = 78). Multivariate analysis showed that factors predicting better outcomes were in serum tumor marker (STM) normalization, RPLND, and extra-RPLN resection. Good outcomes were obtained in patients who completed chemotherapy up to third line. After fourth-line chemotherapy, approximately 50% of “difficult-to-treat” patients could be cured with normalization of STM levels and residual mass resection. Continuous or sequential chemotherapy with multimodality therapy is important for patients with “difficult-to-treat” advanced GCTs. Effective chemotherapy after third line should be developed." @default.
• W2324792835 created "2016-06-24" @default.
• W2324792835 creator A5016761611 @default.
• W2324792835 creator A5022974808 @default.
• W2324792835 creator A5034889609 @default.
• W2324792835 creator A5040656434 @default.
• W2324792835 creator A5041864474 @default.
• W2324792835 creator A5041964655 @default.
• W2324792835 creator A5054076544 @default.
• W2324792835 creator A5056659582 @default.
• W2324792835 creator A5070972892 @default.
• W2324792835 creator A5071095495 @default.
• W2324792835 creator A5086795397 @default.
• W2324792835 creator A5088773176 @default.
• W2324792835 date "2015-03-01" @default.
• W2324792835 modified "2023-10-17" @default.
• W2324792835 title "Importance of Continuous Sequential Chemotherapy and Multimodal Treatment for Advanced Testicular Cancer" @default.
• W2324792835 cites W1666280695 @default.
• W2324792835 cites W1748674096 @default.
• W2324792835 cites W1769875169 @default.
• W2324792835 cites W1868039889 @default.
• W2324792835 cites W1967521966 @default.
• W2324792835 cites W1987222012 @default.
• W2324792835 cites W2001337597 @default.
• W2324792835 cites W2010315611 @default.
• W2324792835 cites W2023765168 @default.
• W2324792835 cites W2041741533 @default.
• W2324792835 cites W2046799168 @default.
• W2324792835 cites W2083477789 @default.
• W2324792835 cites W2088316751 @default.
• W2324792835 cites W2089346683 @default.
• W2324792835 cites W2092323631 @default.
• W2324792835 cites W2095955563 @default.
• W2324792835 cites W2103429415 @default.
• W2324792835 cites W2128723228 @default.
• W2324792835 cites W2156540973 @default.
• W2324792835 cites W2156748324 @default.
• W2324792835 cites W2158112007 @default.
• W2324792835 cites W2172027353 @default.
• W2324792835 cites W4297914219 @default.
• W2324792835 cites W44254208 @default.
• W2324792835 doi "https://doi.org/10.1097/md.0000000000000653" @default.
• W2324792835 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4602480" @default.
• W2324792835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25789960" @default.
• W2324792835 hasPublicationYear "2015" @default.
• W2324792835 type Work @default.
• W2324792835 sameAs 2324792835 @default.
• W2324792835 citedByCount "5" @default.
• W2324792835 countsByYear W23247928352017 @default.
• W2324792835 countsByYear W23247928352018 @default.
• W2324792835 countsByYear W23247928352020 @default.
• W2324792835 countsByYear W23247928352021 @default.
• W2324792835 crossrefType "journal-article" @default.
• W2324792835 hasAuthorship W2324792835A5016761611 @default.
• W2324792835 hasAuthorship W2324792835A5022974808 @default.
• W2324792835 hasAuthorship W2324792835A5034889609 @default.
• W2324792835 hasAuthorship W2324792835A5040656434 @default.
• W2324792835 hasAuthorship W2324792835A5041864474 @default.
• W2324792835 hasAuthorship W2324792835A5041964655 @default.
• W2324792835 hasAuthorship W2324792835A5054076544 @default.
• W2324792835 hasAuthorship W2324792835A5056659582 @default.
• W2324792835 hasAuthorship W2324792835A5070972892 @default.
• W2324792835 hasAuthorship W2324792835A5071095495 @default.
• W2324792835 hasAuthorship W2324792835A5086795397 @default.
• W2324792835 hasAuthorship W2324792835A5088773176 @default.
• W2324792835 hasBestOaLocation W23247928351 @default.
• W2324792835 hasConcept C126322002 @default.
• W2324792835 hasConcept C141071460 @default.
• W2324792835 hasConcept C143998085 @default.
• W2324792835 hasConcept C2776212926 @default.
• W2324792835 hasConcept C2776694085 @default.
• W2324792835 hasConcept C2777132456 @default.
• W2324792835 hasConcept C2777506904 @default.
• W2324792835 hasConcept C2778119113 @default.
• W2324792835 hasConcept C2778203143 @default.
• W2324792835 hasConcept C2778239845 @default.
• W2324792835 hasConcept C2778336483 @default.
• W2324792835 hasConcept C509974204 @default.
• W2324792835 hasConcept C71924100 @default.
• W2324792835 hasConceptScore W2324792835C126322002 @default.
• W2324792835 hasConceptScore W2324792835C141071460 @default.
• W2324792835 hasConceptScore W2324792835C143998085 @default.
• W2324792835 hasConceptScore W2324792835C2776212926 @default.
• W2324792835 hasConceptScore W2324792835C2776694085 @default.
• W2324792835 hasConceptScore W2324792835C2777132456 @default.
• W2324792835 hasConceptScore W2324792835C2777506904 @default.
• W2324792835 hasConceptScore W2324792835C2778119113 @default.
• W2324792835 hasConceptScore W2324792835C2778203143 @default.
• W2324792835 hasConceptScore W2324792835C2778239845 @default.
• W2324792835 hasConceptScore W2324792835C2778336483 @default.
• W2324792835 hasConceptScore W2324792835C509974204 @default.
• W2324792835 hasConceptScore W2324792835C71924100 @default.
• W2324792835 hasIssue "11" @default.
• W2324792835 hasLocation W23247928351 @default.
• W2324792835 hasLocation W23247928352 @default.
• W2324792835 hasLocation W23247928353 @default.
• W2324792835 hasLocation W23247928354 @default.
• W2324792835 hasOpenAccess W2324792835 @default.

• next